Meridian Bioscience Inc. (VIVO) announced that it has received clearance from the U.S. Food and Drug Administration for TRU Legionella, a new rapid assay for detection of legionellosis.
TRU Legionella is a rapid lateral flow device that provides optimized detection of Legionella pneumophila serogroup that is most commonly associated with Legionnaire's disease. Suspected infection is characterized by non-specific upper respiratory symptoms.
For comments and feedback: editorial@rttnews.com